Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine

International Journal of Cardiology

Volumn 127, Issue 3, 2008, Pages

  Cavusoglu, Yuksel ^a   Tek, Mujgan ^a   Birdane, Alparslan ^a   Ata, Necmi ^a   Demirustu, Canan ^a   Gorenek, Bulent ^a   Unalir, Ahmet ^a   Timuralp, Bilgin ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Brain natriuretic peptide; Dobutamine; Levosimendan

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; LEVOSIMENDAN;

ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; TREATMENT RESPONSE;

DOBUTAMINE; HUMANS; HYDRAZONES; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PYRIDAZINES; TREATMENT OUTCOME;

EID: 45849096879     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.136     Document Type: Article

References (19)

1. De Luca L., Colucci W.S., Nieminen M.S., et al. Evidence-based use of levosimendan in different clinical setting. Eur Heart J 27 (2006) 1908-1920
2. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102 (2000) 2222-2227
3. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1903-1912
4. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 360 (2002) 196-202
5. Hastillo A., Taylor D.O., and Hess M.L. Specific positive inotropic agents. In: Messerli F.H. (Ed). Cardiovascular Drug and Therapy. 2nd edition (1996), W.B. Saunders Company, Philadelphia 1151-1161
6. Toller W.G., and Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 104 (2006) 556-569
7. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
8. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
9. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
10. Gegenhuber A., Mueller T., Firlinger F., Lenz K., Poelz W., and Haltmayer M. Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. Clin Chem 50 (2004) 454-456
11. Kyrzopoulos S., Adamopoulos S., Parissis J.T., et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99 (2005) 409-413
12. McLean A.S., Huang S.J., Nalos M., and Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 46 (2005) 830-835
13. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi P., and Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 9 (2007) 75-82
14. Mueller T., Gegenhuber A., and Haltmayer M. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. Int J Cardiol 104 (2005) 355-356
15. Parissis J.T., Panou F., Farmakis D., et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96 (2005) 423-426
16. Parissis J.T., Adamopoulos S., Farmakis D., et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92 (2006) 1768-1772
17. Moertl D., Berger R., Huelsmann M., Bojic A., and Richard P. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail 7 (2005) 1156-1163
18. Adamopoulos S., Parissis J.T., Iliodromitis E.K., et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 98 (2006) 102-106
19. 2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7 (2005) 882-887